- Home
- LBRX vs EHAB Comparison
LBRX vs EHAB Comparison
Compare LBRX & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRX
- EHAB
- Stock Information
- Founded
- LBRX 2015
- EHAB 2014
- Country
- LBRX United States
- EHAB United States
- Employees
- LBRX N/A
- EHAB N/A
- Industry
- LBRX Biotechnology: Pharmaceutical Preparations
- EHAB Hospital/Nursing Management
- Sector
- LBRX Health Care
- EHAB Health Care
- Exchange
- LBRX Nasdaq
- EHAB Nasdaq
- Market Cap
- LBRX 337.7M
- EHAB 403.5M
- IPO Year
- LBRX 2025
- EHAB N/A
- Fundamental
- Price
- LBRX $16.13
- EHAB $8.13
- Analyst Decision
- LBRX Strong Buy
- EHAB Buy
- Analyst Count
- LBRX 3
- EHAB 3
- Target Price
- LBRX $46.33
- EHAB $8.67
- AVG Volume (30 Days)
- LBRX 123.7K
- EHAB 318.5K
- Earning Date
- LBRX 11-21-2025
- EHAB 11-05-2025
- Dividend Yield
- LBRX N/A
- EHAB N/A
- EPS Growth
- LBRX N/A
- EHAB N/A
- EPS
- LBRX N/A
- EHAB N/A
- Revenue
- LBRX N/A
- EHAB $1,037,800,000.00
- Revenue This Year
- LBRX N/A
- EHAB $4.95
- Revenue Next Year
- LBRX N/A
- EHAB $4.51
- P/E Ratio
- LBRX N/A
- EHAB N/A
- Revenue Growth
- LBRX N/A
- EHAB N/A
- 52 Week Low
- LBRX $13.36
- EHAB $6.47
- 52 Week High
- LBRX $20.25
- EHAB $10.91
- Technical
- Relative Strength Index (RSI)
- LBRX N/A
- EHAB 47.52
- Support Level
- LBRX N/A
- EHAB $8.30
- Resistance Level
- LBRX N/A
- EHAB $8.72
- Average True Range (ATR)
- LBRX 0.00
- EHAB 0.30
- MACD
- LBRX 0.00
- EHAB -0.02
- Stochastic Oscillator
- LBRX 0.00
- EHAB 28.87
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.